Table 1 Systematic review of RCTs of omega-3 PUFAs for depression

From: Efficacy of omega-3 PUFAs in depression: A meta-analysis

Author Year Age Comorbidity Antidepressants Clinical diagnosis Rating scales Duration Omega-3 PUFAs
EPA DHA
1. Peet & Horrobin (1 g/d)16 2002 18–70 Mixed With Without HDRS-17/ MADRS/BDI 12 weeks 1000 mg/d /
Peet & Horrobin (2 g/d) 2000 mg/d /
Peet & Horrobin (4 g/d) 4000 mg/d /
2. Nemets et al.17 2002 18–75 Mixed Mixed DSM-IV HDRS-24 4 weeks 2000 mg/d /
3. Su et al.18 2003 18–60 Without Mixed DSM-IV HRSD-21 8 weeks 880 mg/d 440 mg/d
4. Marangell et al.4 2003 18–65 Without Without DSM-IV HDRS-28/ MADRS 6 weeks / 2000 mg/d
5. Hallahan et al.19 2007 16–64 Without With DSM-III HRSD-17/ BDI 12 weeks 1200 mg/d 900 mg/d
6. Grenyer et al.20 2007 18–75 With Mixed DSM-IV HDRS-17 16 weeks 2200 mg/d 600 mg/d
7. Jazayeri et al.21 2008 20–59 Without Without DSM-IV HDRS-24 8 weeks 1000 mg/d /
8. Rogers et al.22 2008 18–70 Mixed Without Without BDI/ DASS 12 weeks 630 mg/d 830 mg/d
9. Lucas et al.23 2009 44–55 Without Without DSM-IV HAMD-21 8 weeks 1150 mg/d 150 mg/d
10. Carney et al.24 2009 adult With With DSM-IV HAMD-17/ BDI-II 10 weeks 930 mg/d 750 mg/d
11. Mischoulon et al.11 2009 18–80 Without Mixed DSM-IV HAMD-17 8 weeks 970 mg/d /
12. Bot et al.25 2010 18–75 With With DSM-IV MADRS 12 weeks 1000 mg/d /
13. Coryell (1 g/d) 2010 18–55 Mixed With DSM-IV MADRS 6 weeks 740 mg/d 400 mg/d
 Coryell (2 g/d) 1480 mg/d 800 mg/d
14. Rondannelli et al.26 2011 65–95 Mixed Without DSM-IV GDS 8 weeks 1670 mg/d 830 mg/d
15. Tajalizadekhoob et al.27 2011 ≥65 With Mixed Without GDS-15 6 months 180 mg/d 120 mg/d
16. Antypa et al.28 2012 18–65 Without Mixed Without BDI 4 weeks 1740 mg/d 250 mg/d
17. Gertsik et al.29 2012 18–65 Mixed With DSM-IV HAMD-21 8 weeks 900 mg/d 200 mg/d
18. Lespérance et al.30 2012 ≥18 Mixed With Without MADRS 8 weeks 1050 mg/d 150 mg/d
19. Mozaffari-Khosravi et al. (DHA)3 2013 18–75 Without With DSM-IV HDRS-17 12 weeks / 1000 mg/d
Mozaffari-Khosravi (EPA) 1000 mg/d /
20. Gharekhani31 2014 Adults With Without Without BDI-21 12 weeks 1080 mg/d 720 mg/d
21. Mischoulon et al. (DHA)32 2015 18–80 Without Without DSM-IV HDRS-17 8 weeks 180 mg/d 900 mg/d
Mischoulon (EPA) 1060 mg/d 274 mg/d
22. Park et al.33 2015 18–65 Without With DSM-IV HAMD-17 12 weeks 1140 mg/d 600 mg/d
23. Ravi et al.34 2016 18–65 With Without Without BDI 8 weeks 720 mg/d 480 mg/d
24. Mazereeuw et al.35 2016 45–80 With Mixed DSM-IV HAMD-17/ BDI-II 12 weeks 1200 mg/d 600 mg/d
25. Shinto et al.36 2016 18–85 With With DSM-IV MADRS/ BDI 3 months 1950 mg/d 1350 mg/d
26. Rapaport et al. (DHA)37 2016 18–80 Without Mixed DSM-IV HAMD-17 8 weeks 180 mg/d 900 mg/d
 Rapaport (EPA) 2016 1160 mg/d 260 mg/d
  1. All 26 trials included in this meta-analysis were double-blind, randomized controlled trials. They were summarized as participants’ age, including with or without clinical diagnosis, kinds of rating scales, received therapy dosage and duration
  2. DSM-IV Diagnostic and Statistical Manual of Mental Disorders (fourth edition), DSM-III Diagnostic and Statistical Manual of Mental Disorders (third edition), HDRS/HAMD-17/21/24 17/21/24-item Hamilton Depression Rating Scale, MADRS Montgomery Asberg Depression Rating Scale, BDI Beck Depression Inventory, GDS Geriatric Depression Scale, omega-3 PUFAs omega-3 polyunsaturated fatty acids, EPA eicosapentaenoic acid, DHA docosahexaenoic acid